跳至主要内容
临床试验/NCT03269435
NCT03269435已完成4 期

A Randomized Trial of Greater Occipital Nerve Block With Bupivacaine Versus Intravenous Metoclopramide for Acute Migraine

Montefiore Medical Center1 个研究点 分布在 1 个国家目标入组 99 人开始时间: 2017年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
99
试验地点
1
主要终点
0-10 Pain Score

研究概览

简要总结

We are comparing a type of nerve block called greater occipital nerve block versus standard therapy among patients who present to an emergency department for acute migraine. This is a randomized, double-blind, double dummy study. The greater occipital nerve block will be performed bilaterally with bupivacaine 0.5%. Standard therapy is metoclopramide 10mg IV.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Double dummy design with IV placebo and placebo nerve block

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eligible patients are adults who present with an acute moderate or severe headache meeting migraine headache criteria, as defined by the International Classification of Headache Disorders-3β (1.1, migraine without aura). Patients who meet criteria for Probable Migraine without Aura (1.5.1) will also be included, provided they have had at least one similar attack previously.

排除标准

  • Patients will be excluded if informed consent cannot be obtained, if there is concern for a secondary cause of headache, if the maximum documented temperature is greater than 100.3 degrees, for a new objective neurologic abnormality, skull defect, suspected infection overlying injection site, known bleeding disorder, ongoing use of anti-platelet agents including P2Y12 platelet inhibitors (clopidogrel, prasugrel, ticagrelor), heparins, warfarin, or 10a inhibitors (rivaroxaban, apixaban, edoxaban, fondaparinux), prior treatment with a greater occipital nerve block, allergy to the investigational medications, pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.

研究组 & 干预措施

Greater Occipital Nerve Block

Experimental

Bilateral greater occipital nerve block with bupivacaine 0.5%

  • Normal saline IV

干预措施: Greater occipital nerve block with bupivacaine (Procedure)

Metoclopramide

Active Comparator

Metoclopramide 10mg IV

  • Bilateral greater occipital nerve block with normal saline

干预措施: Metoclopramide (Drug)

结局指标

主要结局

0-10 Pain Score

时间窗: one hour

Pain score assessed at baseline and one hour. 0= no pain, 10 = worst imaginable. This outcome is the change in pain between baseline and one hour

次要结局

  • Sustained Headache Freedom(48 hours)
  • Sustained Headache Relief(48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Benjamin W. Friedman, MD

Professor

Montefiore Medical Center

研究点 (1)

Loading locations...

相似试验

Greater Occipital Nerve Block Versus Metoclopramide | 临床试验